Incidence and management of arrhythmias in women

Journal of Gender-Specific Medicine

Volumn 5, Issue 4, 2002, Pages 38-48

  Beauregard, Lou Anne M ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMANTADINE; AMIODARONE; ANDROSTANOLONE; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL L TYPE; CATECHOLAMINE; CISAPRIDE; CITALOPRAM; CLINDAMYCIN; DISOPYRAMIDE; ERYTHROMYCIN; ESTRADIOL; ESTROGEN; HALOFANTRINE; HALOPERIDOL; IBUTILIDE; ION CHANNEL; KETOCONAZOLE; PENTAMIDINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROBUCOL; PROCAINAMIDE; PROCHLORPERAZINE; QUINIDINE; SOTALOL; TERFENADINE; TETRACYCLIC ANTIDEPRESSANT AGENT; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMETHOPRIM; UNINDEXED DRUG;

ARTIFICIAL HEART PACEMAKER; BODY SIZE; COMORBIDITY; DEFIBRILLATOR; FEMALE; FOOD DRUG INTERACTION; HEART ARRHYTHMIA; HEART DEATH; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE ARRHYTHMIA; HORMONAL REGULATION; HUMAN; LONG QT SYNDROME; MALE; MENSTRUAL CYCLE; MORTALITY; NONHUMAN; PREGNANCY; PUBERTY; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; SYMPTOMATOLOGY;

ADOLESCENT; ARRHYTHMIA; CLINICAL TRIALS; FEMALE; HUMANS; INCIDENCE; MALE; MENOPAUSE; MIDDLE AGED; PREGNANCY; PUBERTY; SEX FACTORS; TACHYCARDIA, VENTRICULAR;

EID: 0036663677     PISSN: 15237036     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Manolio TA, Furberg CD, Rautaharju PM, et al. Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: The Cardiovascular Health Study. J Am Coll Cardiol 1994;23:916-925.
2. Sobotka PA, Mayer JH, Bauernfeind RA, et al. Arrhythmias documented by 24-hour continuous ambulatory electrocardiographic monitoring in young women without apparent heart disease. Am Heart J 1981;101:753-759.
3. Romhilt DW, Chaffin C, Choi SC, Irby EC. Arrhythmias on ambulatory electrocardiographic monitoring in women without apparent heart disease. Am J Cardiol 1984;54:582-586.
4. Rodriguez LM, de Chillou C, Schläpfer J, et al. Age at onset and gender of patients with different types of supraventricular tachycardias. Am J Cardiol 1992;70:1213-1215.
5. Stramba-Badiale M, Spagnolo D, Bosi G, Schwartz PJ, for the MISNES Investigators. Are gender differences in QTc present at birth? Multicenter Italian Study on Neonatal Electrocardiography and Sudden Infant Death Syndrome. Am J Cardiol 1995;75:1277-1278.
6. Burke JH, Goldberger JJ, Ehlert FA, et al. Gender differences in heart rate before and after autonomic blockade: Evidence against an intrinsic gender effect. Am J Med 1996; 100:537-543.
7. Dhingra RC, Rosen KM, Rahimtoola SH. Normal conduction intervals and responses in sixty-one patients using His bundle recording and atrial pacing. Chest 1973;64:55-59.
8. Schneider JF, Thomas HE Jr, Sorlie P, et al. Comparative features of newly acquired left and right bundle branch block in the general population: The Framingham Study. Am J Cardiol 1981;47:931-940.
9. Morady F, Higgins J, Peters RW, et al. Electrophysiologic testing in bundle branch block and unexplained syncope. Am J Cardiol 1984;54:587-591.
10. Larsen JA, Kadish AH. Effects of gender on cardiac arrhythmias. J Cardiovasc Electrophysiol 1998;9:655-664.
11. Meyer R, Linz KW, Surges R, et al. Rapid modulation of L-type calcium current by acutely applied oestrogens in isolated cardiac myocytes from human, guinea-pig and rat. Exp Physiol 1998;83:305-321.
12. Tanabe S, Hata T, Hiraoka M. Effects of estrogen on action potential and membrane currents in guinea pig ventricular myocytes. Am J Physiol 1999;277(2 Pt 2):H826-H833.
13. Drici MD, Burklow TR, Haridasse V, et al. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-1474.
14. Nakajima T, Iwasawa K, Oonuma H, et al. Antiarrhythmic effect and its underlying ionic mechanism of 17beta estradiol in cardiac myocytes. Br J Pharmacol 1999; 127:429-440.
15. Li HY, Bian JS, Kwan YW, Wong TM. Enhanced responses to 17beta-estradiol in rat hearts treated with isoproterenol: Involvement of a cyclic AMP-dependent pathway. J Pharmacol Exp Ther 2000;293:592-598.
16. Jovanovic S, Jovanovic A, Shen WK, Terzic A. Low concentrations of 17beta estradiol protect single cardiac cells against metabolic stress-induced Ca2+ loading. J Am Coll Cordial 2000;36:948-952.
17. Rosano GM, Leonardo F, Dicandia C, et al. Acute electrophysiologic effect of estradiol 17beta in menopausal women. Am J Cardiol 2000;86:1385-1387.
18. Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: Relations to age and gender over nine decades. J Am Coll Cardiol 1998;31:593-601.
19. Ali YS, Daamen N, Jacob G, et al. Orthostatic intolerance: A disorder of young women. Obstet Gynecol Surv 2000;55:251-259.
20. Krahn, AD, Yee R, Klein GJ, Morillo C. Inappropriate sinus tachycardia: Evaluation and therapy. J Cardiovasc Electrophysiol 1995:6:1124-1128.
21. Huikuri HV, Pikkujämsä SM, Airaksinen KE, et al. Sex-related differences in autonomic modulation of heart rate in middle-aged subjects. Circulation 1996;94:122-125.
22. Ramaekers D, Ector H, Aubert AE, et al. Heart rate variability and heart rate in healthy volunteers: Is the female autonomic nervous system cardioprotective? Eur Heart J 1998; 19:1334-1341.
23. Rosano GM, Patrizi R, Leonardo F, et al. Effect of estrogen replacement therapy on heart rate variability and heart rate in healthy post-menopausal women. Am J Cardiol 1997;80:815-817.
24. s contributes to the longer action potential of the M cell. Circ Res 1995:76:351-365.
25. Anyukhovsky EP, Sosunov EA, Rosen MR. Regional differences in electro-physiological properties of epicardium, midmyocardium and endocardium: In vitro and in vivo correlations. Circulation 1996;94:1981-1988.
26. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: Evaluation of clinical and experimental evidence. J Womens Health 1998;7:547-557.
27. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: Findings from the International LQTS Registry. Circulation 1998;97:2237-2244.
28. Rodriguez AM, de Chillou C, Schläpfer J, et al. Age at onset and gender of patients with different types of supraventricular tachycardias. Am J Cardiol 1992;70:1213-1215.
29. Fuenmayor AJ, Araujo X, Fuenmayor AM. Cardiac arrhythmias during two different stages of the menstrual cycle. lnt J Cardiol 1998;63:267-270.
30. Myerburg RJ, Cox MM, Interian A Jr, et al. Cycling of inducibility of paroxysmal supraventricular tachycardia in women and its implications for timing of electrophysiologic procedures. Am J Cardiol 1999;83:1049-1054.
31. Burke JH, Ehlert FA, Kruse JT et al. Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults. Am J Cardiol 1997;79:178-181.
32. Rashba EJ, Zareba W, Moss AJ, et al, for the LQTS Investigators. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. Circulation 1998;97:451-456.
33. Shotan A, Ostrzega E, Mehra A, et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol 1997;79:1061-1064.
34. Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995;130:871-876.
35. Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993;36:137-178.
36. Dominguez A, Iturralde P, Hermosillo AG, et al. Successful radiofrequency ablation of an accessory pathway during pregnancy. Pacing Clin Electrophysiol 1999;22(1 Pt 1):131-134.
37. Brodsky M, Doria R, Allen B, et al. New-onset ventricular tachycardia during pregnancy. Am Heart J 1992;123(4 Pt 1):933-941.
38. Natale A, Davidson T, Geiger MJ, Newby K. Implantable cardioverter-defibrillators and pregnancy: A safe combination? Circulation 1997;96:2808-2812.
39. Larsen JA, Tung RH, Sadananda R, et al. Effects of hormone replacement therapy on QT interval. Am J Cardiol 1998;82:993-995.
40. Dahlberg ST. Gender difference in the risk factors for sudden cardiac death. Cardiology 1990;77(supp 2):31-40.
41. Albert CM, McGovern BA, Newell JB, Ruskin JN. Sex differences in cardiac arrest survivors. Circulation 1996;93:1170-1176.
42. Perers E, Abrahamsson P, Bang A, et al. There is a difference in characteristics and outcome between women and men who suffer out of hospital cardiac arrest. Resuscitation 1999;40:133-140.
43. Buxton AE, Lee KL, Fisher JD, et al, for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-1890.
44. Moss AJ, Hall WJ, Cannom DS, et al, for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-1940.
45. The Amiodarone Vs Implantable Defibrillators Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583.
46. Russo AM, Stamato N, Pieper KS. Gender differences in the Multicenter Unsustained Tachycardia Trial [abstract]. Circulation 1999;100:1-657. Presented at: Annual Scientific Session of the American Heart Association, 1999.
47. Vaitkus PT, Kindwall KE, Miller JM, et al. Influence of gender on inducibility of ventricular arrhythmias in survivors of cardiac arrest with coronary artery disease. Am J Cardiol 1991:67:537-539.
48. Horton HL, Marinchak RA, Rials SJ, Kowey PR. Gender differences in device therapy for malignant ventricular arrhythmias. Arch Intern Med 1995;155:2342-2345.
49. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol 1992;20:1391-1396.
50. Gussak I, Antzelevitch C, Bjerregaard P, et al. The Brugada syndrome: Clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol 1999;33:5-15.
51. Gasparini M, Priori SG, Mantica M, et al. High positivity and reproducibility of programmed electrical stimulation in the Brugada syndrome [abstract]. Pacing Clin Electrophysiol 2001;24:606.
52. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
53. Lehmann MH, Hardy 5, Archibald D, et al. Sex difference in the risk of torsade cle pointes with d,I-sotalol. Circulation 1996;94:2535-2541.
54. Fredlund BO, Olsson SB. Long QT interval and ventricular tachycardia of "torsade de pointe" type in hypothyroidism. Acta Med Scand 1983;213:231-235.
55. Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest 1994;105:368-372.
56. Lopez JA, Harold JG, Rosenthal MC, et al. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cordial 1987:59:376-377.
57. Gabel A, Schymik G, Mehmel HC. Ventricular fibrillation due to long OT syndrome probably caused by clindamycin. Am J Cardiol 1999;83:813-815.
58. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequenes. JAMA 1993;269:1513-1518.
59. Wharton JM, Demopulos PA, Goldschlager N. Torsade de pointes during administration of pentamidine isethionate. Am J Med 1987;83:571-576.
60. Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of anti-malarial treatment with halofantrine. Lancet 1993;341:1054-1056.
61. Sartori M, Pratt CM, Young JB. Torsade de pointe: Malignant cardiac arrhythmia induced by amantadine poisoning. Am J Med 1984;77:388-391.
62. Giles TD, Modlin RK. Death associated with ventircular arrhythmia and thioridazine hydrochloride. JAMA 1968;205:108-110.
63. Elkayam U, Frishman W. Cardiovascular effects of phenothiazines. Am Heart J 1980:100;397-401.
64. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993;119:391-394.
65. Glassman AH. Cardiovascular effects of antidepressant drugs: Updated. J Clin Psychiatry 1998;59(suppl 15):13-18.
66. Hermann HC, Kaplan LM, Bierer BE. Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 1983;51:904-906.
67. Personne M, Persson H, Sjöberg E. Citalopram toxicity. Lancet 1997;350:518-519.
68. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986;111:1088-1093.
69. Strasberg B, Sclarovsky S, Erdberg A, et al. Procainamide-induced polymorphous ventricular tachycardia. Am J Cardiol 1981;47:1309-1314.
70. Tzivoni D, Keren A, Stern S, Gottlieb S. Disopyramide-induced torsade de pointes. Arch Intern Med 1981;141:946-947.
71. Olshansky B, Martins J, Hunt S. N-acetyl procainamide causing torsades de pointes. Am J Cardiol 1982;50:1439-1441.
72. Stambler BS, Wood MA, Ellenbogen KA, et al, for the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-1621.
73. Sclarovsky S, Lewin RF, Kracoff O, et al. Amiodarone-induced polymorphous ventricular tachycardia. Am Heart J 1983; 105:6-12.
74. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction: Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-865.
75. Wesley RC Jr, Turnquest P. Torsades de pointe after intravenous adenosine in the presence of prolonged OT syndrome. Am Heart J 1992;123:794-796.
76. Craft TM. Torsade de pointes after astemizole overdose. Br Med J (Clin Res Ed) 1986;292:660.
77. Pinto YM, van Gelder IC, Heeringa M, Crijns HJ. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 1999;353:980.
78. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-2790.
79. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-291.
80. Endo T, Katoh T, Kiuchi K, et al. Famotidine and acquired long Qt syndrome. Am J Med 2000;108:438-439.
81. Gohn DC, Simmons TW. Polymorphic ventricular tachycardia (torsade de pointes) associated with the use of probucol. N Engl J Med 1992;326:1435-1436.
82. Young JB, Vandermolen LA, Pratt CM. Torsade de pointes: An unusual manifestation of chloral hydrate poisoning. Am Heart J 1986;112:181-184.
83. Nora M, Elsner G, Purdy C, Zipes DP. Wide QRS rhythm due to taxine toxicity. J Cardiovasc Electrophysiol 1993;4:59-61.
84. Little RE, Kay GN, Cavender A et al. Torsade de pointes and T-U alternans associated with arsenic poisoning. Pacing Clin Electrophysiol 1990;13:164-170.
85. Ludomirsky A, Klein HO, Sarelli P, et al. QT prolongation and polymorphous ("torsade de pointes") ventricular arrhythmias associated with organophosphorus insecticide poisoning. Am J Cardiol 1982;49:1654-1658.
86. Chao CL, Chen WJ, Wu CC, Lee YT. Torsade dee pointes and T-wave alternans in a patient with brainstem hemorrhage. Int J Cardiol 1995;51:199-201.
87. Isner JIM, Sours HE, Paris AL, et al. Sudden, unexpected death in avid dieters using the liquid-protein-modified-fast diet: Observations in 17 patients and the role of the prolonged QT interval. Circulation 1979;60:1401-1412.
88. Kawasaki R, Machado C, Reinoehl J, et al. Increased propensity of women to develop torsades de pointes during complete heart block. J Cardiovasc Electrophysiol 1995;6:1032-1038.
89. Janosik D, Stratman HG, Walter KE, Kennedy HL. Torsade de pointes: A rare complication of temporary pacing for permanent ventricular pacemaker failure. Pacing Clin Electrophysiol 1985;8:558-561.
90. Gettes LS. Electrolyte abnormalities underlying lethal and ventricular arrhythmias. Circulation 1992;85(1 suppl):170-176.
91. Kambara H, Itfield BJ, Phillips J. Hypocalcemia and intractable ventricular fibrillation. Ann Intern Med 1977;86:583-584.
92. Topol EJ, Lerman BB. Hypomagnesemic torsades de pointes. Am J Cardiol 1983;52:1367-1368.
93. Griffin J, Most AS. Torsade de pointes complicating acute myocardial infarction. Am Heart J 1984;107:169-170.
94. Kocheril AG, Bokhari SA, Batsford WP, Sinusad AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997;20:2810-2816.
95. Grapefruit juice interactions with drugs. Med Lett Drugs Ther 1995;37:73-74.
96. Leitersdorf E, Goshen R, Shefer A. Atypical ventricular tachycardia in combined tetracyclic, antidepressant, neuroleptic and anticholinergic drugs interaction. Int J Psychiatry Med 1982;12:85-91.
97. Vitullo RN, Wharton JM, Allen NB, Pritchell EL. Trazodone-related exercise-induced nonsustained ventricular tachycardia. Chest 1990;98:247-248.
98. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000;11:691-696.
99. Michaud GF, Wang E, Kirk MM, Buxton AE. The prevalence of the Brugada ECG pattern among patients presenting to the emergency department with tricyclic antidepressant ingestion [abstract]. Pacing Clin Electrophysiol 2001;24:589.
100. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: A report of 24 adult cases. Circulation 1982;65:384-398.
101. Belhassen B, Viskin S. Indiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol 1993;4:356-368.
102. Lamas GA, Pashos CL, Normand SI, McNeil B. Permanent pacemaker selection and subsequent survival in elderly Medicare pacemaker recipient. Circulation 1995;91:1063-1069.
103. Schüppel R, Büchele G, Batz L, Koenig W. Sex differences in selection of pacemakers: Retrospective observational study. BMJ 1998;316:1492-1495.
104. Raj SR, Brennan FJ, Abdollah H. Is there a sex bias in the selection of permanent pacemaker implantation? Can J Cardiol 1996;12:375-378.
105. Kiviniemi MS, Pirnes MA, Eränen HJ, et al. Complications related to permanent pacemaker therapy. Pacing Clin Electrophysiol 1999;22:711-720.
106. Ausubel K, Furman S. The pacemaker syndrome. Ann Intern Med 1985;103:420-429.
107. Hesselson AB, Parsonnet V, Bernstein AD, Bonavita GJ. Deleterious effects of long-chamber ventricular pacing in patients with sick sinus syndrome: The hidden benefits of dual-chamber pacing. J Am coll Cardiol 1992;19:1542-1549.
108. Rothenberger-Janzen K, Flueckiger A, Bigler R. Carcinoma of the breast and pacemaker generators. Pacing Clin Electrophysiol 1998;21(4 Pt 1):769-771.
109. Shen WK, Hammill SC, Hayes DL, et al. Long-term survival after pacemaker implantation for heart block in patient ≥ 65 years. Am J Cardiol 1994;74:560-564.
110. Kudenchuk PJ, Bardy GH, Poole JE, et al. Malignant sustained ventricular tachyarrhythmias in women: Characteristics and outcome of treatment with an implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 1997;8;2-10.